The impact of the use of metformine for obese pregnant women in prevention

• Autor(a) principal: do Nascimento, Iramar Baptistella
• Data de Publicação: 2020
• Outros Autores: Sales, Willian Barbosa, Dienstmann, Guilherme, de Souza, Matheus Leite Ramos, Fleig, Raquel, Silva, Jean Carl
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Scientia Medica (Porto Alegre. Online)
• Texto Completo: https://revistaseletronicas.pucrs.br/scientiamedica/article/view/35338
• topic: obesity; pregnancy; metformin; preeclampsia; obesidade; gravidez; metformina; pré-eclâmpsia

Aims: The article aims to evaluate the use of metformin in obese pregnant women in the prevention of pre-eclampsia.Methods: This is a randomized clinical trial with obese pregnant women with a body mass index greater than or equal to 30 kg / m2 divided into two groups: a study group that used metformin and a control group that followed the prenatal routine. The pregnant women entered the study with gestational age less than 20 weeks and were followed throughout the prenatal period. The diagnosis of pre-eclampsia was made according to World Health Organization criteria.Results: The absolute risk reduction and number needed to treat in a 95% confidence interval for the preeclampsia result were checked. In the results, 272 pregnant women were evaluated. In the study group (n = 127) eight (6.3%) developed preeclampsia, in the control group (n = 145) 31 (21.4%) obtained the disease (p <0.01).Conclusions: The study indicated an absolute risk reduction of 15.1 times (95% CI: 7.1-22.9) and number needed to treat of 7 (95%CI: 4.4-13.9). The use of 1000 milligrams daily metformin indicated a 15.1 x reduction in the absolute risk of preeclampsia in the study population, with the need to treat seven pregnant women to avoid an outcome.